225 related articles for article (PubMed ID: 23702644)
1. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
[No Abstract] [Full Text] [Related]
3. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
4. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
Abd-Elazeem MA; Abd-Elazeem MA
Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
[TBL] [Abstract][Full Text] [Related]
5. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
7. Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers.
Rao D; Kimler BF; Nothnick WB; Davis MK; Fan F; Tawfik O
Hum Pathol; 2015 Jun; 46(6):876-83. PubMed ID: 25841305
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
11. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
12. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
13. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
[TBL] [Abstract][Full Text] [Related]
14. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
15. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
